International Journal of Hematology and Oncology 2023, Vol 33, Num 4 Page(s): 255-260
Stereotactic Radiosurgery in Pituitary Adenomas: A Single Center Experience

Serdar SURENKOK1, Omer SAGER1, Ferrat DINCOGLAN1, Hakan GAMSIZ1, Selcuk DEMIRAL1, Bora UYSAL1, Sait SIRIN2, Kaan OYSUL1, Murat BEYZADEOGLU1

1Gulhane Military Medical Academy, Department of Radiation Oncology, Ankara, TURKEY
2Gulhane Military Medical Academy, Department of Neurosurgery Ankara, TURKEY

Keywords: Pituitary adenoma, Stereotactic radiosurgery, Growth hormone
The aim of this study was to evaluate the efficiency of stereotactic radiosurgery (SRS) in the management of pituitary adenomas. Between June 1998 and July 2011, 57 patients with pituitary adenomas were treated using SRS at our department. All patients underwent high-precision single dose SRS using a linear accelerator with 6-MV photons. Median follow-up time was 31.5 (3-92) months. Median age was 40 years (range: 19-57 years). Radiological tumor growth control was achieved in 48 patients (84.2%) (a decrease in tumor size in 25 patients and no change in tumor size in 23 patients). 13 patients with functioning adenomas had available biochemical follow-up and biochemical complete response was achieved in 8 (61.5%) of these 13 patients. Treatment of pituitary adenomas using LINAC-based single dose SRS is safe and effective in improving local tumor and biochemical control.